How Cipo's 2026 Patentable Subject‑matter Guidance Will Change Pharmaceutical & Biotech Patent Litigation in Canada

Last reviewed: May 1, 2026

On March 24, 2026, the Canadian Intellectual Property Office (CIPO) published a practice notice that fundamentally resets how patent examiners assess patentable subject‑matter under the Patent Act, and the ripple effects for pharmaceutical and biotech patent litigation are already being felt. This new CIPO patentable subject‑matter guidance 2026 Canada framework replaces earlier examiner approaches with a structured, stepwise test that will change which claims survive prosecution, which validity arguments gain traction in PM(NOC) proceedings, and how evidence is marshalled before the Federal Court. For general counsel, in‑house IP teams and patent litigators across the life‑sciences sector, the notice demands an immediate reassessment of pending applications, existing patent portfolios and litigation strategy.

This article delivers a litigation‑first tactical playbook, from claim drafting redlines to expert‑witness planning, designed for counsel who need to act now.

Key Takeaways

• New examiner test. CIPO’s March 24, 2026 practice notice introduces a stepwise framework for assessing whether claims define patentable subject‑matter, replacing prior ad‑hoc approaches.
• Biotech and pharma claims at heightened risk. Diagnostic methods, certain medical‑use claims, and abstract biological correlations face increased scrutiny at the prosecution stage, and correspondingly sharper invalidity attacks in litigation.
• PM(NOC) proceedings will be reshaped. Patentable subject‑matter is likely to become a more prominent validity issue in PM(NOC) actions, affecting both pleading strategy and evidence preparation.
• Claim drafting must adapt immediately. Structural, machine‑tied and composition‑based claim formats will be critical to surviving both prosecution and litigation challenges under the new guidance.
• Federal Court weight remains an open question. Practice notices are not binding law, courts retain independent authority on patentable subject‑matter, but the guidance will inevitably influence expert evidence and judicial reasoning.

Background: Patentable Subject‑Matter in Canada, A Legal Primer

Canadian patent law defines an “invention” in section 2 of the Patent Act as any new and useful art, process, machine, manufacture or composition of matter, or any new and useful improvement thereof. This statutory definition has remained unchanged for decades, but its interpretation, particularly as applied to biotechnology, diagnostics and computer‑implemented inventions, has been shaped by a series of Federal Court and Federal Court of Appeal decisions that left practitioners navigating considerable uncertainty.

Five Requirements for Patentability

Key Court Decisions That Prompted the Practice Notice

The evolution of patentable subject‑matter in Canada 2026 did not occur in a vacuum. The Federal Court of Appeal’s jurisprudence on the boundary between abstract ideas and patentable inventions created a patchwork of standards that CIPO’s Manual of Patent Office Practice (MOPOP) struggled to reconcile. Courts have consistently held that mere scientific principles, abstract theorems and methods of medical treatment fall outside the statutory definition, while acknowledging that practical applications of scientific discoveries can qualify as patentable subject‑matter. The tension between these principles, especially in the context of diagnostic assays, personalised medicine and gene‑based therapies, created the policy impetus for CIPO’s updated guidance.

On March 23, 2026, Innovation, Science and Economic Development Canada (ISED) published a related consultation, signalling the broader policy context that led to the practice notice issued the following day.

CIPO Practice Notice 2026: Summary of the New Test

The CIPO practice notice 2026 establishes a structured analytical framework that examiners must apply when assessing whether claims define patentable subject‑matter. Published on March 24, 2026, the notice replaces earlier guidance and introduces a stepwise approach designed to bring consistency to an area of examination that had produced divergent outcomes.

The Stepwise Framework

Under the new test, examiners are directed to undertake a purposive analysis of the claims to identify the essential elements of the invention, then determine whether those essential elements, taken together, define subject‑matter that falls within the statutory categories of section 2. The test requires examiners to distinguish between elements that represent a practical application, producing a physical effect or change, and elements that constitute a disembodied idea, abstract theorem or mere intellectual process. Where the essential elements of a claim amount to nothing more than an abstract idea or scientific principle, the claim will be found to lack patentable subject‑matter regardless of how it is formally drafted.

The notice emphasises that claim language alone cannot transform non‑patentable subject‑matter into a patentable invention. Examiners are instructed to look beyond the form of the claim to its substance, meaning that boilerplate recitations of physical steps, generic computer implementation, or standard laboratory procedures will not save a claim whose inventive contribution resides in an abstract correlation or mental process.

Official Examples

Alongside the practice notice, CIPO published a companion document providing detailed examples of patentable subject‑matter analysis. These examples cover categories of direct relevance to biotech and pharma, including diagnostic methods, methods of medical treatment, computer‑implemented biological analyses, and claims directed to naturally occurring substances. The examples illustrate both claims that pass the new test and claims that do not, providing a practical reference point for patent agents and litigators alike. Industry observers expect these examples to become frequently cited in both prosecution arguments and Federal Court proceedings as the new framework is applied across existing and new filings.

How the Guidance Changes Biotech and Pharma Patentability

The practical impact of CIPO’s patentable subject‑matter guidance 2026 Canada falls unevenly across different claim types. Biotech patentability Canada now requires careful attention to how inventive contributions are characterised, with certain categories of claims facing materially higher prosecution risk.

Risk Assessment by Claim Type

Claim Redline Examples

The following before‑and‑after examples illustrate how biotech claims can be restructured to improve resilience under the new framework:

Example 1, Diagnostic Method Claim

• Before: “A method of diagnosing condition X in a patient, comprising determining the level of biomarker Y in a sample, and correlating said level with the presence of condition X.”
• After: “A method of detecting biomarker Y in a biological sample, comprising: (a) contacting the sample with reagent Z under conditions sufficient to form a detectable complex; (b) measuring the complex using [specific instrument/technique]; and (c) generating a quantitative output indicative of the level of biomarker Y.”
• Why this helps: The revised claim anchors the inventive contribution in physical assay steps rather than the mental act of correlation. The diagnostic conclusion is removed from the claim scope, reducing abstract‑idea vulnerability.

Example 2, Personalised Dosage Claim

• Before: “A method of treating disease X comprising administering compound A to a patient identified as having genotype B, wherein the dose is adjusted based on the patient’s genotype.”
• After: “A pharmaceutical composition comprising compound A in a unit dosage form of [specific mg range] for use in treating disease X in a patient population characterised by genotype B.”
• Why this helps: Reframing as a composition‑for‑use claim shifts the inventive contribution from a treatment method (excluded) to the composition itself (patentable), while preserving the genotype limitation as a defined patient population.

Example 3, Gene‑Editing Method

• Before: “A method of modifying gene G in a cell, comprising designing a guide RNA targeting sequence S and introducing said guide RNA with a Cas9 protein into the cell.”
• After: “A system for modifying gene G comprising: (i) an engineered guide RNA having sequence S; and (ii) a Cas9 protein complexed with said guide RNA, wherein the system effects a double‑strand break at locus L of gene G when introduced into a eukaryotic cell.”
• Why this helps: Casting the invention as a physical system (composition of components) rather than a method of designing a guide RNA avoids the abstract‑idea objection inherent in the “designing” step.

Implications for PM(NOC) Litigation and Patent Validity Strategy

The PM(NOC) litigation strategy landscape shifts materially after the March 2026 guidance. Patentable subject‑matter has historically been a secondary validity argument in PM(NOC) proceedings, overshadowed by anticipation, obviousness and insufficiency. Early indications suggest that dynamic will change, as generic manufacturers and biosimilar applicants gain a structured framework to mount subject‑matter challenges with greater precision.

How Subject‑Matter Arguments Reshape PM(NOC) Validity Pleadings

Under the Patented Medicines (Notice of Compliance) Regulations, a second person (generic or biosimilar manufacturer) who challenges the validity of a listed patent can assert that the patent does not claim patentable subject‑matter. Previously, this argument was difficult to frame concisely because CIPO’s own approach lacked a clear, citable test. The 2026 practice notice changes that calculus. While the Federal Court is not bound by CIPO guidance, the existence of a detailed, stepwise framework, complete with published examples, provides second persons with a structured template for invalidity allegations and a foundation for expert evidence.

For innovators (first persons), the defensive challenge is equally clear: patent portfolios that include claims vulnerable to subject‑matter attack must be shored up before litigation, either through prosecution amendments or by ensuring that claim construction arguments can distinguish the inventive contribution from the abstract elements the practice notice targets.

Sample Litigation Positions

Tactical Checklist for PM(NOC) Plaintiffs and Defendants

For innovators (first persons):

• Audit all patents listed on the Patent Register for subject‑matter vulnerability under the new stepwise test.
• Prepare claim‑construction arguments demonstrating that essential elements are physical, tangible and fall within section 2 categories.
• Retain expert witnesses with hands‑on laboratory experience in the relevant technology (molecular biology, assay development, formulation science) to testify on physical implementation.
• Consider filing continuation or divisional applications with claim formats aligned to the new guidance as defensive portfolio strategy.
• Brief litigation counsel on prosecution history, any examiner objections related to subject‑matter that were overcome should be documented and prepared for cross‑examination.

For generics and biosimilar applicants (second persons):

• Review listed patents to identify claims where the inventive contribution arguably resides in an abstract correlation, mental step or diagnostic conclusion.
• Structure invalidity allegations using the language and stepwise framework of the CIPO practice notice.
• Retain experts who can deconstruct claims to isolate the abstract core from the physical implementation steps.
• Anticipate that innovators will argue the practice notice is non‑binding, prepare judicial authority establishing that CIPO guidance, while not determinative, is relevant to claim construction and validity analysis.
• Consider timing implications: raising subject‑matter invalidity early may streamline the proceeding and reduce reliance on costly prior‑art searches.

Practical PM(NOC) Strategy and Claim Drafting Playbook

Adapting claim drafting to the CIPO patentable subject‑matter guidance 2026 Canada framework is not merely a prosecution exercise, it is a litigation preparation discipline. Every claim drafted today is a claim that will be construed, attacked and defended in a Federal Court proceeding years from now. The choices made at the drafting stage directly determine the strength of invalidity defences and the scope of available remedies.

Prosecution Strategy: Core Principles

• Lead with composition claims. Pharmaceutical compositions, formulations and biological constructs (engineered proteins, recombinant vectors, guide RNA systems) remain the strongest claim format under the new guidance. These should form the core of any patent portfolio.
• Use Swiss‑type and medical‑use formats for therapeutic claims. Where method‑of‑treatment claims face exclusion, reframing as “use of compound X for the treatment of disease Y” or “compound X for use in treating disease Y” preserves commercial coverage while reducing subject‑matter risk.
• Anchor method claims in physical transformation. Any process claim must identify specific, tangible steps that produce a physical effect, not merely the recognition or correlation of a biological phenomenon.
• Include fallback claim sets. Draft a tiered portfolio with broad independent claims and progressively narrower dependents that incorporate additional physical limitations, ensuring at least some claims survive even aggressive prosecution.
• Document the inventive contribution contemporaneously. Laboratory notebooks, experimental protocols and inventor declarations should clearly record the physical implementation of the invention, this documentation becomes critical evidence in litigation.

Freedom to Operate Considerations

Freedom to operate biotech Canada assessments must now account for the possibility that competitor patents containing vulnerable claim types may be narrowed or invalidated under the new guidance. Conversely, FTO opinions should flag that competitors may amend or refile claims in formats that are more resilient. Any FTO analysis conducted before March 2026 should be updated to reflect the new prosecution landscape.

Suggested Claim Portfolio Template

Evidence, Experts and Invalidity Defences: What to Prepare Now

The shift in patent validity Canada 2026 analysis means that evidence strategy in PM(NOC) and Federal Court proceedings must adapt in three specific areas: expert selection, demonstrative evidence and the substantive theories of invalidity that will gain traction.

Expert Witness Selection

The new guidance places a premium on experts who can explain the physical implementation of biotechnology inventions in accessible terms. Experts with bench‑level laboratory experience, molecular biologists, assay development scientists, formulation chemists, will be more effective than purely academic witnesses at demonstrating whether a claim’s essential elements involve tangible physical steps or remain in the realm of abstract correlation. Both sides should retain experts early and ensure their reports address the stepwise framework directly.

Invalidity Theories Gaining Traction

• Abstract idea / mere scientific principle. The most direct theory: the essential elements of the claim define nothing more than a correlation, algorithm or natural phenomenon without practical application.
• Diagnostic method exclusion. Claims directed to diagnostic conclusions, even if wrapped in laboratory steps, where the inventive contribution is the correlation between marker and disease.
• Method of medical treatment. Reinforced by the practice notice; claims whose substance is the treatment of a patient by a physician, regardless of claim format.
• Insufficiency / lack of enablement. Where claims are narrowed to specific physical implementations, the disclosure must enable those implementations, creating a secondary vulnerability if the specification is thin on experimental detail.

Evidence Timeline for PM(NOC) Proceedings

Expert Report Outline Checklist

• Identify the essential elements of each asserted claim through purposive construction.
• Apply the CIPO stepwise framework to each claim: do the essential elements define a practical application with a physical result?
• Explain the state of the art and what the skilled person would understand as the inventive contribution.
• Address whether the recited physical steps are routine or represent the true locus of invention.
• Provide opinion on whether the claim, if stripped of its abstract or correlative elements, retains patentable substance.
• Support conclusions with reference to CIPO examples where analogous claim types are analysed.

Federal Court Patent Litigation Canada: Injunctions, Remedies and Appeals

Federal Court patent litigation Canada will feel the downstream effects of the practice notice even though CIPO guidance does not bind the courts. The likely practical effect will be twofold: first, Federal Court judges will encounter more detailed and structured subject‑matter arguments in validity challenges, potentially increasing the rate at which such arguments succeed; second, the practice notice and its examples will be cited by expert witnesses and in written submissions as persuasive authority on how the skilled person understands the boundary of patentable subject‑matter.

Reliefs and Recommended Evidence

On appeal, the Federal Court of Appeal will ultimately determine how much weight CIPO’s stepwise framework carries in judicial analysis. Industry observers expect early appellate decisions to establish whether the practice notice is treated as merely one input among many or as a persuasive interpretive tool. Counsel should monitor these decisions closely and be prepared to adjust litigation strategy as the case law develops.

Timeline of Key Dates

Conclusion: Immediate Action Checklist for In‑House Counsel

The CIPO patentable subject‑matter guidance 2026 Canada framework is not a distant policy development, it is an operational reality that demands immediate attention from every life‑sciences legal team with Canadian patent exposure. The following eight‑point checklist provides a starting framework for action:

1. Audit pending applications. Review all pending Canadian patent applications for claims that may be vulnerable under the new stepwise test, with priority given to diagnostic, personalised‑medicine and method‑of‑treatment claims.
2. Update claim drafting templates. Ensure prosecution counsel and patent agents are using claim formats aligned with the new guidance, composition‑first, Swiss‑type medical use, and physically anchored method claims.
3. Review Patent Register listings. For patents listed on the Patent Register for PM(NOC) purposes, assess whether any claims are subject to heightened invalidity risk and consider whether divisional or continuation strategies are warranted.
4. Brief litigation counsel. Ensure that Federal Court litigation teams understand the new framework, have access to the CIPO examples, and are prepared to address subject‑matter arguments in both offensive and defensive postures.
5. Retain and brief expert witnesses. Identify and retain experts with bench‑level scientific experience who can credibly address the physical‑implementation requirements of the stepwise test.
6. Re‑run freedom‑to‑operate assessments. Any FTO analysis completed before March 24, 2026 should be revisited to account for the possibility that competitor claims may be narrowed or invalidated.
7. Review PM(NOC) dockets. For active PM(NOC) proceedings, assess whether subject‑matter invalidity should be added or strengthened as a ground of challenge.
8. Monitor Federal Court developments. Track early judicial treatment of the practice notice to calibrate litigation strategy as the case law evolves.

The stakes for getting this right are significant. Patent portfolios worth hundreds of millions of dollars in Canadian market exclusivity may be strengthened or weakened by how effectively counsel responds to the 2026 changes. Proactive adaptation, in prosecution, litigation preparation and portfolio management, is the only prudent course. Find Canadian IP Litigation lawyers through Global Law Experts to obtain tailored advice on your specific portfolio and litigation exposure.

Sources

1. Innovation, Science and Economic Development Canada, March 24, 2026 Practice Notice on Patentable Subject‑Matter
2. Innovation, Science and Economic Development Canada, Examples of Patentable Subject‑Matter Analysis
3. McMillan LLP, Updated Guidance from CIPO on Patentable Subject‑Matter
4. Smart & Biggar, All about CIPO’s 2026 Updated Guidelines
5. <a href="https://gowlingwlg.com/en/insights-resources/articles/2025/